PAVmed Inc
PAVM
View Detailed Chart
10.800USD
+0.220+2.08%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
8.30MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+2.08%
5 Days
+39.35%
1 Month
+54.73%
6 Months
+2226.58%
Year to Date
+63.04%
1 Year
+1659.24%
View Detailed Chart
TradingKey Stock Score of PAVmed Inc
Currency: USD Updated: 2026-02-06Key Insights
PAVmed Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is good.Its valuation is considered fairly valued, ranking 122 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 315.00.In the medium term, the stock price is expected to remain stable.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
PAVmed Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
PAVmed Inc Highlights
StrengthsRisks
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates in the medical devices, diagnostics, and digital health sectors. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 694.43% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 3.00M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Undervalued
The company’s latest PE is -3.57, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 96.72K shares, increasing 26.46% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 11.41K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.27.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
315.000
Target Price
+2877.32%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
PAVmed Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
PAVmed Inc Info
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates in the medical devices, diagnostics, and digital health sectors. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.
Ticker SymbolPAVM
CompanyPAVmed Inc
CEOAklog (Lishan)
Websitehttps://pavmed.com/
Related Instruments
+2.98%
+0.07%
+1.60%
+2.48%
+0.31%
-1.14%
-0.05%
-2.35%
-1.78%
+2.65%
+2.59%
+2.03%
+2.01%
+2.38%
+1.74%
+0.16%
+0.78%
+1.72%
+0.59%
-2.02%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
69601.180
-368.950 (-0.53%)
282.580
+22.390 (+8.61%)
2102.820
+51.090 (+2.49%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
